PUBLIC COMPANY
saveBOEHRINGER INGELHEIM
USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
- phase1A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
- phase2A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
- phase3Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- phase2A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- phase3A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- phase2A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
- phase1A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
🐶 Hiring Signal
Where BOEHRINGER INGELHEIM is staffing up — a leading indicator of pipeline and commercial priorities.
News
- STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and moreThe U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providersstat · 2d ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 3d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 3d ago
- Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againDespite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…biospace · 3d ago
- #EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesityMILAN — Boehringer Ingelheim’s lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes, according to data presented Thursda…endpoints · 3d ago
- Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…fiercebiotech · 3d ago
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…endpoints · 9d ago
- 9 pharma leaders sound ‘alarm bells’ on biotech’s decline in EuropeFrustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”biopharma_dive · 11d ago
- Boehringer adds $250M to value of Variant pact by expanding into cardiovascular diseaseBoehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.fiercebiotech · 11d ago
- Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsViking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more tha…biospace · 12d ago
comments(0)
5-min edit window · permanent after that